Unison Clinical Trials

Sherman Oaks, California 991403

1 studies enrolling now · 15 studies all time

What they study most

Atopic Dermatitis, Colorectal Cancer, Dermatitis, Atopic, Irritable Bowel Syndrome With Diarrhea (IBS-D), Moderate Psoriasis, Moderate to Severe Plaque Psoriasis, Plaque Psoriasis, Psoriasis, Psoriasis (PsO), Severe Psoriasis

Studies at this site

• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) — Recruiting now
• Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis — Running, not enrolling
• To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis — Completed
• To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis — Completed
• Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis — Stopped early
• A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Completed
• Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis — Status unconfirmed
• A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis — Completed
• Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C" — Completed
• Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C" — Completed
• Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis — Completed
• A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) — Completed
• Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis — Status unconfirmed
• A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome — Completed
• A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis — Completed